Adaptive Biotechnologies Appoints New CMO, Officer Departs
Ticker: ADPT · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $380,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Adaptive Bio just swapped CMOs, Markowitz in, Carder out, effective April 4th.
AI Summary
Adaptive Biotechnologies Corporation announced on April 9, 2024, that its Board of Directors appointed Dr. Jessica S. Markowitz as Chief Medical Officer, effective April 4, 2024. The company also announced the departure of Dr. Lance D. Carder as Chief Medical Officer on April 4, 2024. Additionally, the company filed its financial statements and exhibits.
Why It Matters
Changes in key executive positions like the Chief Medical Officer can signal shifts in a company's strategic direction, particularly in the biotech sector where medical leadership is crucial for product development and clinical trials.
Risk Assessment
Risk Level: medium — Executive departures and appointments, especially for critical roles like CMO, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Adaptive Biotechnologies Corporation (company) — Registrant
- Dr. Jessica S. Markowitz (person) — Appointed Chief Medical Officer
- Dr. Lance D. Carder (person) — Departed Chief Medical Officer
- April 4, 2024 (date) — Effective date of appointment and departure
- April 9, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jessica S. Markowitz has been appointed as the new Chief Medical Officer.
When did the new Chief Medical Officer's appointment become effective?
The appointment of Dr. Jessica S. Markowitz as Chief Medical Officer became effective on April 4, 2024.
Who has departed from the role of Chief Medical Officer?
Dr. Lance D. Carder has departed from the role of Chief Medical Officer.
On what date did Dr. Lance D. Carder's departure become effective?
Dr. Lance D. Carder's departure as Chief Medical Officer was effective on April 4, 2024.
What is the filing date of this Current Report on Form 8-K?
This Current Report on Form 8-K was filed on April 9, 2024.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-04-09 17:29:02
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ADPT The Nasdaq Stock Mar
- $380,000 — y that provides for an annual salary of $380,000 per year and an annual target bonus of
Filing Documents
- d814314d8k.htm (8-K) — 26KB
- d814314dex101.htm (EX-10.1) — 12KB
- g814314page1a.jpg (GRAPHIC) — 10KB
- g814314page1b.jpg (GRAPHIC) — 12KB
- 0001193125-24-090983.txt ( ) — 177KB
- adpt-20240404.xsd (EX-101.SCH) — 3KB
- adpt-20240404_lab.xml (EX-101.LAB) — 17KB
- adpt-20240404_pre.xml (EX-101.PRE) — 11KB
- d814314d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Executive Employment Agreement between the Company and Kyle Piskel dated April 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Adaptive Biotechnologies Corporation Date: April 9, 2024 By: /s/ Chad Robins Chad Robins Chief Executive Officer